
Biotech firm specializing in proprietary cancer therapies and diagnostic solutions.
NED Biosystems, a Public Benefit Corporation, was founded with the mission to develop safe, efficacious, and comprehensive systems treatments for complex diseases, starting with cancer. Their core vision is to enable patients to achieve and sustain No Evidence of Disease (NED). The company specializes in proprietary combination cancer therapies and diagnostic solutions, employing a systems-based approach that targets the entire biological system rather than isolated components.
Notable affiliated individuals and investors include experts in oncology and biotechnology. NED Biosystems has achieved significant milestones in developing their patented NED- treatment for cancer. Their innovative approach has garnered attention in the biotech community, contributing to advancements in cancer therapy and diagnostics. The overall impact of NED Biosystems lies in its potential to transform cancer treatment paradigms and improve patient outcomes globally.

Nerx Biosciences

NED Medical
nedmedical.com

Neodiagnostix
neodiagnostix.com

Kronos Bio

Neoantigenics

Manhattan BioSolutions

Palm Therapeutics

Nested Therapeutics
nestedtx.com

CNine Biosolutions

Nantkwest

Nereid Therapeutics
nereidtx.com
Nina Biotherapeutics

Nido Biosciences
nidobio.com

NKT Therapeutics

Know Bio
knowbiollc.com
Companies similar to NED Biosystems include Nerx Biosciences, NED Medical, Neodiagnostix and Kronos Bio.
NED Biosystems was founded in 2008.
NED Biosystems' headquarters is located in Cambridge, MA, US.
NED Biosystems' most recent funding round was for $2M (USD) in August 2018.
As of Aug 6, 2018, NED Biosystems has raised a total of $3.5M (USD).
NED Biosystems has 30 employees as of Feb 5, 2024.